ES2524006T3 - Inhibición del crecimiento celular - Google Patents

Inhibición del crecimiento celular Download PDF

Info

Publication number
ES2524006T3
ES2524006T3 ES07119791.7T ES07119791T ES2524006T3 ES 2524006 T3 ES2524006 T3 ES 2524006T3 ES 07119791 T ES07119791 T ES 07119791T ES 2524006 T3 ES2524006 T3 ES 2524006T3
Authority
ES
Spain
Prior art keywords
cell growth
inhibition
erbb
cell
arresting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES07119791.7T
Other languages
English (en)
Inventor
Mingdong Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zensun Shanghai Science and Technology Ltd
Original Assignee
Zensun Shanghai Science and Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3815248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2524006(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zensun Shanghai Science and Technology Ltd filed Critical Zensun Shanghai Science and Technology Ltd
Application granted granted Critical
Publication of ES2524006T3 publication Critical patent/ES2524006T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C03—GLASS; MINERAL OR SLAG WOOL
    • C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
    • C03C17/00—Surface treatment of glass, not in the form of fibres or filaments, by coating
    • C03C17/34—Surface treatment of glass, not in the form of fibres or filaments, by coating with at least two coatings having different compositions
    • C03C17/3411—Surface treatment of glass, not in the form of fibres or filaments, by coating with at least two coatings having different compositions with at least two coatings of inorganic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Geochemistry & Mineralogy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

Uso de un anticuerpo anti-ErbB-3 para la fabricación de un medicamento para el tratamiento de un cáncer con sobreexpresión de ErbB-2, donde el anticuerpo anti-ErbB-3 previene o reduce la formación del heterodímero ErbB-2/ErbB-3.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8

Claims (1)

  1. imagen1
ES07119791.7T 1999-06-18 2000-06-16 Inhibición del crecimiento celular Expired - Lifetime ES2524006T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ105799 1999-06-18
AUPQ1057A AUPQ105799A0 (en) 1999-06-18 1999-06-18 Cell growth inhibition

Publications (1)

Publication Number Publication Date
ES2524006T3 true ES2524006T3 (es) 2014-12-03

Family

ID=3815248

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07119791.7T Expired - Lifetime ES2524006T3 (es) 1999-06-18 2000-06-16 Inhibición del crecimiento celular

Country Status (8)

Country Link
US (2) US9783456B1 (es)
EP (3) EP1187634B1 (es)
JP (1) JP4674020B2 (es)
AT (1) ATE381943T1 (es)
AU (1) AUPQ105799A0 (es)
DE (1) DE60037586T2 (es)
ES (1) ES2524006T3 (es)
WO (1) WO2000078347A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
CN1447696A (zh) 2000-05-19 2003-10-08 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
AU2008200654B2 (en) * 2001-08-09 2010-04-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Inhibitors of HER3 activity
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
US7919098B2 (en) 2002-03-26 2011-04-05 Zensun ( Shanghai ) Sci & Tech Co., Ltd. ErbB-3 based methods and compositions for treating neoplasms
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
ES2710439T3 (es) 2005-01-21 2019-04-25 Genentech Inc Dosificación fija de anticuerpos HER
KR101253576B1 (ko) 2005-02-23 2013-04-11 제넨테크, 인크. Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
EP2091975A4 (en) 2006-11-21 2013-05-22 Univ California ANTIBODIES TO THE EGFR FAMILY, BICE-SPECIFIC ANTIBODIES TO THE EGFR FAMILY AND METHOD FOR THEIR USE
EP2518508A1 (en) 2006-11-28 2012-10-31 U3 Pharma GmbH Activated HER3 as a marker for predicting therapeutic efficacy
SG178789A1 (en) 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
EP2899541A1 (en) 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
CA2690334C (en) 2007-06-08 2017-02-14 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2010019952A2 (en) 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
EP2808339B1 (en) 2008-11-28 2017-02-15 Zensun (Shanghai) Science & Technology, Co., Ltd. Neuregulin peptides and their use
SG10201402742YA (en) 2009-03-20 2014-08-28 Genentech Inc Bispecific anti-her antibodies
JP5705836B2 (ja) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター
BR112012012160B1 (pt) * 2009-11-13 2022-04-26 Amgen, Inc. Material e métodos para tratar ou prevenir doenças associadas ao her-3
PH12012501157A1 (en) 2009-12-22 2012-10-29 Roche Glycart Ag Anti-her3 antibodies and uses thereof
KR20130000384A (ko) 2010-02-18 2013-01-02 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 뉴레귤린 길항제 및 암의 치료에서의 그의 용도
KR101798679B1 (ko) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
KR101862832B1 (ko) * 2010-11-01 2018-05-30 심포젠 에이/에스 Ｐａｎ―ｈｅｒ 항체 조성물
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
US20140363438A1 (en) 2011-08-17 2014-12-11 Genentech, Inc. Neuregulin antibodies and uses thereof
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
MX350957B (es) 2011-11-23 2017-09-27 Medimmune Llc Moleculas de union especificas para her3 y usos de las mismas.
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
RU2014136886A (ru) 2012-03-27 2016-05-20 Дженентек, Инк. Диагностика и виды лечения, связанные с ингибиторами her3
HK1202431A1 (en) 2012-05-02 2015-10-02 Symphogen A/S Humanized pan-her antibody compositions
BR112015006656A8 (pt) 2012-10-08 2020-01-21 Sensun Shanghai Science & Tech Co Ltd composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos
JP6998646B2 (ja) 2012-11-30 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
EP2999499B1 (en) 2013-05-22 2019-07-17 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for treating heart failure
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE463851B (sv) 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
EP0444181B2 (en) 1989-08-04 2010-11-24 Bayer Schering Pharma Aktiengesellschaft C-erbb-2 external domain: gp75
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5578482A (en) * 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
DE4221256C2 (de) 1992-06-26 1997-07-10 Lancaster Group Ag Galenische Zusammensetzung für die topische Anwendung
US5741511A (en) 1995-04-12 1998-04-21 Sam Yang Co., Ltd. Transdermal drug delivery device for treating erectile dysfunction
WO1997023256A1 (en) 1995-12-22 1997-07-03 Localmed, Inc. Localized intravascular delivery of growth factors for promotion of angiogenesis
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
AU727082B2 (en) * 1996-03-27 2000-11-30 Genentech Inc. ErbB3 antibodies
WO1998002540A1 (en) 1996-07-12 1998-01-22 Genentech, Inc. Chimeric heteromultimer adhesins
EP0931147A1 (en) * 1996-10-18 1999-07-28 Genentech, Inc. ANTI-ErbB2 ANTIBODIES
US5981201A (en) 1997-01-08 1999-11-09 Beth Israel Deaconess Medical Center Methods of detection and treatment of breast cancer
DE69840699D1 (de) 1997-02-10 2009-05-14 Genentech Inc Heregulin varianten
SE9703226D0 (sv) 1997-09-08 1997-09-08 Astra Ab New pharmaceutical composition
US6197801B1 (en) 1998-01-14 2001-03-06 Usa Doctors Products, Inc. Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction
AU784617B2 (en) 2000-05-15 2006-05-18 Pharmacia & Upjohn Company Aromatase inhibitors and monoclonal anti-HER2 antibodies as antitumors agents
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
US7919098B2 (en) 2002-03-26 2011-04-05 Zensun ( Shanghai ) Sci & Tech Co., Ltd. ErbB-3 based methods and compositions for treating neoplasms
JP2008531557A (ja) 2005-02-23 2008-08-14 メリマック ファーマシューティカルズ インコーポレーティッド 生物活性を調節するための二重特異性結合剤
SG178789A1 (en) 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof

Also Published As

Publication number Publication date
DE60037586D1 (de) 2008-02-07
DE60037586T2 (de) 2009-01-08
EP2810653B1 (en) 2020-01-08
US9783456B1 (en) 2017-10-10
EP1187634A1 (en) 2002-03-20
EP1889631A1 (en) 2008-02-20
EP1187634A4 (en) 2005-06-15
JP4674020B2 (ja) 2011-04-20
ATE381943T1 (de) 2008-01-15
JP2003502386A (ja) 2003-01-21
EP1187634B1 (en) 2007-12-26
EP2810653A1 (en) 2014-12-10
WO2000078347A1 (en) 2000-12-28
US20160152727A1 (en) 2016-06-02
EP1889631B1 (en) 2014-09-03
AUPQ105799A0 (en) 1999-07-08

Similar Documents

Publication Publication Date Title
ATE381943T1 (de) Zellwachstumsinhibition
ES2269118T5 (es) Antagonistas de HMG1 para el tratamiento de afecciones inflamatorias
SV2004001432A (es) 2-tio-3,5-diciano-4-4fenil-6-aminopiridinas substituidas y su uso ref. lea 35 640-sv
NL300242I1 (nl) Mega-carboxyaryl gesubstitueerde difenylureums alsraf kinaseremmers.
CY1108095T1 (el) Αντικαρκινικα αναλογα της ετ-743
DZ3186A1 (fr) Ptéridinones utilisées comme inhibiteurs de kinase.
UY34152A (es) ?oxazolidinonas substituidas y su uso?.
ITRM910660A0 (it) Dispositivo di illuminazione per un microscopio operatorio.
ECSP034600A (es) Compuestos de lactama
BR9814361A (pt) Inibição de quinase raf usando uréiasheterocìclicas substituìdas por arila eheteroarila
CY1113054T1 (el) Παραγωγα διαμινης
EP2289894A3 (en) Pyrrolo-triazine compounds useful as kinase inhibitors
EA200100773A1 (ru) Замещенные 1-гетероциклические диариламины
UY26451A1 (es) Procedimiento para la obtención de 1,2,3,4- tetrahidroquinolinas 4-carboxiamino-2-sustituidas
BG103310A (en) Benzonaphthyridins as bronchial therapeutical means
YU39803A (sh) Jedinjenja piperazinilpirazina kao agonisti ili antagonisti serotonin 5ht-2-receptora
NO950220D0 (no) Fremgangsmåte for heving av gjenstander fra havbunnen
ATE135000T1 (de) Substituierte benzonitrile
EA200100854A1 (ru) Кальций-литические соединения
ES2104682T3 (es) Fluor-compuestos.
TR199901017A2 (xx) B�cek ilac� terkibi.
DE60008400D1 (de) Triazolopyrimidinderivate
BR0010317A (pt) Bandeja de armazenagem para refrigerador
ATE232081T1 (de) Orale zusammensetzung enthaltend perlit
EA200200798A1 (ru) Кальцилитические соединения